Bay 41-4109 (C09-1113-061)

BAY 41-4109 is a potent inhibitor of human hepatitis B virus ( HBV ) with an IC 50 of 53 nM.In VitroBAY 41-4109 is able to both accelerate and misdirect capsid assembly in vitro . Preformed capsids are stabilized by BAY 41-4109, up to a ratio of one inhibitor molecule per two dimers. BAY 41-4109 is equally effective at inhibiting HBV DNA release and the cytoplasmic HBcAg level, with IC 50 s of 32.6 and 132 nM in HepG2.2.15 cells, respectively. HBV DNA and HBcAg are inhibited in a dose-dependent manner, indicating that the anti-HBV mechanisms are associated with and dependent on the rate of HBcAg inhibition. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoBAY 41-4109 reduces viral DNA in the liver and in the plasma dose-dependently with efficacy comparable to 3TC. BAY 41 -4109 reduces hepatitis B virus core antigen (HBcAg) in livers of HBV-transgenic mice. Pharmacokinetic studies in mice have shown rapid absorption, a bioavailability of 30% and dose-proportional plasma concentrations, about 60% in rats and dogs .BAY41-4109 inhibits virus production in vivo by a mechanism that targets the viral capsid. MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:SolidIC50& Target:IC50&Target: 53 nM (HBV). Specification: 0.98 Molecular Formula: C18H13ClF3N3O2 Molecular Weight: 395.76 PubChem CID: 489221 Isomeric SMILES: CC1=C([C@@H](N=C(N1)C2=C(C=C(C=N2)F)F)C3=C(C=C(C=C3)F)Cl)C(=O)OC